Novo Nordisk UK has announced that NovoSeven – its recombinant activated factor VII product available for the treatment of bleeding episodes in people with haemophilia with inhibitors – is now available as a room temperature stable formulation from today onwards. This replaces the previous formulation, which required refrigeration.
This new formulation, which is stable at temperatures up to 25°C, enables patients to administer treatment effectively and quickly after the onset of bleeding in any setting.
...gives you the confidence to be the best nurse you can be. Our online learning units, clinical practice articles, news and opinion stories, helps you increase your skills and knowledge and improves your practice.